STING-IN-13 is a selective STING inhibitor that effectively suppresses downstream signaling of the STING pathway and STING-mediated inflammation. It exhibits low toxicity and is suitable for research related to STING-associated inflammatory and autoimmune diseases.

STING-IN-13 (Compound HY2) at a concentration of 30 μM interacts directly with STING in RAW264.7 cells. Pre-treatment with STING-IN-13 (0.03 μM-0.3 μM for 1 hour, followed by co-incubation for 2-4 hours) effectively inhibits downstream signaling in the STING pathway induced by SR717 in THP1 and RAW264.7 cells, significantly reducing the production of inflammatory factors IFN-β and CXCL10. At concentrations of 0.4 μM-3.3 μM over 48 hours, STING-IN-13 demonstrates excellent safety with low cytotoxicity in THP1 cells. Additionally, STING-IN-13 (5 μM, pre-treatment for 1 hour followed by treatment for 2 hours) specifically inhibits STING-driven IFNβ expression in THP1 cells without affecting the TLR pathway.

STING-IN-13 (Compound HY2) (10,20 mg/kg, i.p. one dose) enhances survival rates and protects renal and hepatic function in a cisplatin-induced AKI mouse model, while also reducing tubular damage and inflammatory cell infiltration.